KAI vs REGN · P/E 36, rev $1.05B vs P/E 14, rev $14.34B
Kadant Inc (KAI) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Kadant Inc (KAI) is a specialty industrial machinery company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported KAI revenue for 2024-12-28 was $1.05B. Net income was $112.6M. Revenue was up 10.0% from 2023-12-30 to 2024-12-28. KAI currently screens at market cap $3.69B and trailing P/E 35.6.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
KAI currently screens at market cap $3.69B and trailing P/E 35.6. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the KAI and REGN stock pages for the full models.
Not investment advice.